
	Where results make sense

Topic: Ivax Pharmaceuticals

Related Topics

Galena

In the News (Fri 25 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	IVAX Pharmaueuticals (Site not responding. Last check: 2007-10-26)
		IVAX Pharmaceuticals, Inc., headquartered in Miami, Florida, develops, manufactures, and markets brand equivalent (generic) pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers, and government agencies in the United States.
		IVAX Pharmaceuticals is a subsidiary of Miami-based IVAX Corporation, which is engaged in the research, development, manufacture, and marketing of branded and brand equivalent pharmaceuticals worldwide.
		IVAX Pharmaceuticals is one of the premier brand equivalent drug companies in the U.S., with an estimated 6% of the domestic market.
	www.ivaxpharmaceuticals.com /aboutus.html (248 words)

	IVAX Pharmaceuticals Issues a Nationwide Recall of Goldline Brand Extra Strength Genapap and Extra Strength Genebs
		IVAX Pharmaceuticals is voluntarily recalling the aforementioned lots.
		IVAX Pharmaceuticals method of distribution is through direct accounts, which includes wholesalers and retail pharmacies.
		IVAX is notifying the direct account customers/distributors and direct ship customers who have purchased these products and lots via first class mail recall notification.
	www.fda.gov /oc/po/firmrecalls/ivax05_06.html (440 words)

	IVAX: Subsidiaries
		IVAX Pharmaceuticals UK – (London, England; Runcorn, UK; Waterford, Ireland) develops, manufacturers and markets branded and brand-equivalent prescription and OTC products in the U.K., Ireland and other countries.
		IVAX Pharmaceuticals SRO – (Opava, Czech Republic) Develops, produces and sells Active Pharmaceutical Ingredients (´Substances´) worldwide and finished pharmaceuticals and food supplements in Central and Eastern Europe and in the Middle East markets.
		IVAX Argentina – (Buenos Aires, Argentina) Develops, manufactures and markets a wide variety of pharmaceuticals in Argentina, Peru and Uruguay.
	ivax.com /jsps/subsidiaries/subsidiaries.jsp (488 words)

	IVAX expands respiratory products franchise in Europe
		IVAX Pharmaceuticals and 3M today confirmed the signing of a pan-European agreement in which IVAX has agreed to assume exclusive rights to 3M's hydrofluoroalkane (HFA) beclomethasone and salbutamol brands and devices in nine European countries.
		IVAX markets and is developing a variety of asthma drugs in aerosol as well as non-aerosol dry-powder formulations.
		IVAX also markets Steri-Nebformulations of ipratropium bromide and salbutamol for use in nebulizers to treat asthma and chronic obstructive pulmonary disease.
	cms.3m.com /cms/GB/en/0-12/kkzeuFD/view.jhtml (611 words)

	Announced Action for April 7, 2005
		IVAX had been the first ANDA filer to submit Paragraph IV certifications for the delisted patents and claimed entitlement to a 180-day marketing exclusivity period for generic simvastatin tablets on that basis.
		IVAX contended that the FDA’s regulations required that the patents be relisted, that subsequent ANDAs for simvastatin (from other companies) include certifications for the two patents, and that the FDA not approve those ANDAs until at least 180 days after IVAX’s first commercial marketing of simvastatin tablets.
		According to the FTC, IVAX characterizes its eligibility for the 180-day exclusivity period as a right – based on its filing of a first ANDA containing a Paragraph IV certification for simvastatin – that cannot be divested even when that eligibility is based on an erroneously listed patent.
	www.ftc.gov /opa/2005/04/fyi0525.htm (799 words)

	Priority Solutions International - February 2005
		IVAX Pharmaceuticals develops, manufactures, and markets brand equivalent (generic) pharmaceutical products, which are sold to wholesalers, retail drug chains, retail pharmacies, hospital groups, nursing home providers, and government agencies in the United States.
		IVAX is heavily dependent on the effectiveness of their sales force in marketing their latest products to the medical industry through distributing samples and educating physicians.
		Since DSI began servicing the pharmaceutical industry in 1993, their ability to create a customized distribution solution for each client then perform to a level that meets and exceeds expectations has been one of the cornerstones of their success.
	www.prioritysolutions.com /index.php?option=com_content&task=view&id=91&Itemid=411 (470 words)

	IVAX UK: Corporate Information (Site not responding. Last check: 2007-10-26)
		IVAX Pharmaceuticals UK, IVAX Corporation’s largest European subsidiary, is engaged in the research, development, manufacturing and marketing of branded and brand equivalent (generic) pharmaceuticals.
		A leading supplier of generic medicines, with over 300 product lines, IVAX Pharmaceuticals UK is the UK industry leader in first-to-market generic alternatives and our new product availability is second to none.
		With the UK market for generic pharmaceuticals valued at a total of £1.7 billion in 2003 more than three quarters of all UK prescriptions are now written generically and more than half are dispensed as generics.
	www.ivax.co.uk /jsps/corporate (282 words)

	IVAX Generics Company Intelligence Report
		IVAX’ generic drug strategy is to develop speciality drugs that should encounter relatively little competition.
		In Europe, IVAX subsidiaries include IVAX Pharmaceuticals UK, which develops, manufactures and sells branded and generic products in the United Kingdom, Ireland and other countries, and IVAX Pharmaceuticals SRO in the Czech Republic, which develops, manufactures and markets pharmaceuticals, mainly to the Eastern European market.
		IVAX Scandinavia AB is based in Sweden, and markets and sells proprietary and generic products in Scandinavia and the European Union.
	www.marketresearch.com /researchindex/977727.html (485 words)

	Bloomberg.com: Investment Tools (Site not responding. Last check: 2007-10-26)
		The benefit of the breath-activated Easi-Breathe is that it eliminates the need to coordinate the manual release of the medication with the inhalation of the medicine which is required by the standard metered dose aerosol inhaler.
		In the United States, IVAX has filed an NDA for a CFC-free formulation of albuterol, a rescue medicine for asthma, in the Easi-Breathe device and has received an "approvable" letter from the Federal Food and Drug Administration (FDA) in July 2004.
		IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.
	quote.bloomberg.com /apps/news?pid=conewsstory&refer=conews&tkr=IVX:US&sid=aCUfqYPyGG3I (577 words)

	BioSpace News for IVAX Corporation (Site not responding. Last check: 2007-10-26)
		IVAX Corporation (AMEX:IVX - news; LSE:IVX.L) today reported an 86% increase in net income to $243 million, or $1.19 per share, for the year ended December 31, 2001 from net income of $131 million, or $.64 per share, reported a year ago.
		IVAX Corporation (AMEX:IVX - news; LSE:IVX.L) announced today that the Abbreviated New Drug Application (ANDA) for the brand equivalent (generic) drug tramadol hydrochloride tablets in 50 mg strength has been transferred to IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc., from Able Laboratories, Inc.
		IVAX Corporation (AMEX:IVX - news; LSE:IVX.L) announced today it has received final approval for its Abbreviated New Drug Application (ANDA) for sales of metformin hydrochloride tablets in 500 mg, 625 mg, 750 mg, 850 mg and 1000 mg strengths from the United States Food and Drug Administration (FDA).
	www.acor.org /drugs/pipeline/companies/news/2274.news.orig (533 words)

	Biospace.com (Site not responding. Last check: 2007-10-26)
		This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Doxycycline hyclate 20 mg tablets is the generic equivalent of Periostat(R) Tablets, which is marketed by CollaGenex Pharmaceuticals, Inc. for the treatment of bacterial infections and adult periodontitis.
		Ivax had filed an appeal in the United States Court of Appeals for the District of Columbia seeking to reverse a District Court decision upholding Alpharma's right to exclusivity for gabapentin capsules and tablets.
		In consideration for Ivax's agreement to dismiss the litigation, the company has agreed to allow Ivax to enter into the gabapentin capsule and tablet markets on March 23, 2005 and April 29, 2005, respectively, prior to the lapse of the company's first-to-file exclusivity period.
	www.biospace.com /news_company.aspx?CompanyID=565020&SR=21 (1308 words)

	IVAX Pharmaceuticals UK Limited, from Think London - Business White Papers, Webcasts and Case Studies - BNET.com
		Overview: Leading American drugs company, IVAX Pharmaceuticals Inc, set up IVAX Pharmaceuticals UK in 1994 in the Royal Docks, east London.
		In 1994 IVAX Corporation saw the opportunity for a major drive into Europe and after reviewing a number of locations, including Ireland and Germany, the company decided on London for the location of its new European headquarters.
		IVAX Pharmaceuticals UK is engaged in the research, development, manufacture and marketing of branded and brand equivalent pharmaceuticals worldwide and is now one of the UK's top ten pharmaceutical companies, with over 300 product lines and sales of more than ú145million.
	industries.bnet.com /casestudy.aspx?docid=107624 (448 words)

	IVAX to Market Tramadol Business Wire - Find Articles
		IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that the Abbreviated New Drug Application (ANDA) for the brand equivalent (generic) drug tramadol hydrochloride tablets in 50 mg strength has been transferred to IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc., from Able Laboratories, Inc. (OTCBB:ABRX).
		IVAX currently has 38 ANDAs and four tentative approvals pending at the FDA and is continuing its aggressive filing schedule for new ANDA submissions.
		IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing, and marketing of branded and brand equivalent pharmaceuticals and veterinary products in the U.S. and international markets.
	www.findarticles.com /p/articles/mi_m0EIN/is_2002_Jan_28/ai_82247798 (245 words)

	IVAX gets FDA okay for hydrochlorothiazide; morphine sulphate CR tablets, hypertension management (Site not responding. Last check: 2007-10-26)
		Neil Flanzraich, vice chairman and president of IVAX Corporation, said the company's income before income taxes for the second quarter of this year was $65.1 million compared to $58.2 million in the second quarter of 2004.
		Ivax said it did not include profit from the sale of the generic version of Zocor, which is expect to be launched in the middle of 2006 in the guidance.
		IVAX’ branded respiratory product, albuterol sulfate HFA (CFC-free) in a standard metered dose inhaler, launched in the fourth quarter of 2004, is presently vying for the number one market share position among HFA albuterol products.
	www.dancewithshadows.com /hara/morphine-sulphate-hypertension.asp (1356 words)

	Schizophrenia Daily News Blog: Ivax to offer Clozapine
		IVAX Corporation: announced today that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clozapine tablets USP, 200 mg.
		This product will be sold through IVAX' wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Clozapine is the generic equivalent of Clozaril(R) which is marketed by Novartis and used in the treatment of schizophrenia.
		IVAX currently has a market share of 53% of the total (Clozaril and its generic equivalent combined) market's extended units.
	www.schizophrenia.com /sznews/archives/002794.html (237 words)

	IVAX Receives Final Approval and First to File Status on Gabapentin Tablets
		Tablets in the 100 mg, 300 mg and 400 mg dosage strengths are not currently marketed and IVAX intends to market them through its wholly owned subsidiary, IVAX Pharmaceuticals, Inc. IVAX is able to launch these tablets at any time and is considering a variety of factors in determining when to launch.
		IVAX has also just received tentative approval from the FDA for its ANDA for gabapentin tablets in 600 mg and 800 mg dosage strengths, currently marketed by Warner-Lambert, and had previously received a tentative approval from the FDA on its ANDA for the 100 mg, 300 mg, and 400 mg capsules, currently marketed by Warner-Lambert.
		IVAX is presently litigating whether its gabapentin products infringe a patent held by Pfizer.
	www.omniomix.com /inthenews.php?id=21956 (409 words)

Try your search on: Qwika (all wikis)